IP Library › Granted Patent US 9,399,676
Granted Patent B2
US 9,399,676 · App. 14/795,033 · Granted Jul 26, 2016

Compositions and methods for growth factor modulation

Inventors: Thomas Schurpf (Cambridge, MA); Nagesh K. Mahanthappa (Cambridge, MA); Michelle Marie Straub (Brighton, MA)
Assignee: SCHOLAR ROCK, INC.
C07K16/22C07K14/495C07K16/005C07K16/2863C12N15/1037A61K38/00C07K2317/21C07K2317/24C07K2317/31C07K2317/565C07K2317/76C07K2317/92C07K2317/94G01N2333/71
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,399,676
App. No.
14/795,033
Granted
Jul 26, 2016
Kind
B2
Abstract

Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins.

Claims (14)

1. A method of producing an antibody capable of binding a growth factor prodomain complex (GPC), said GPC consisting of at least one GDF-8 growth factor and at least one GDF-8 prodomain, said method comprising:

a. expressing proGDF-8 (SEQ ID NO: 5),

b. forming the GPC by subjecting the expressed proGDF-8 (SEQ ID NO: 5) to enzymatic cleavage with one or more of furin, bone morphogenetic protein-1 (BMP-1), mammalian tolloid protein (mTLD), mammalian tolloid-like 1 (mTLL1), and mammalian tolloid-like 2 (mTLL2),

c. carrying out solid-phase or solution-phase enrichment with an antibody fragment phage display library, wherein the GPC formed by enzymatic cleavage is used as a target antigen;

d. selecting phage particles bound to the GPC formed by enzymatic cleavage; and

e. producing recombinant antibodies having complementarity determining region (CDR) amino acid sequences obtained from the antibody fragments expressed at the surface of the phage particles selected in (d).

2. The method of claim 1 , further comprising

f. conducting a negative selection binding assay of the recombinant antibodies produced in (e) to remove antibodies that bind to one or more undesired antigens.

3. The method of claim 2 , wherein said one or more undesired antigens are selected from the group consisting of GDF-8 prodomain, GDF-8 growth factor, murine proGDF-8, proGDF-11, proTGF-β1 and a protein with an amino acid sequence selected from the group consisting of SEQ ID NOs: 207-230.

4. The method of claim 1 , wherein phage particle binding is determined using one or more binding assays selected from the group consisting of enzyme-linked immunosorbent assays, surface plasmon resonance assays, and flow cytometry assays.

5. The method of claim 1 , wherein said enzymatic cleavage comprises sequential enzymatic cleavage with at least two enzymes.

6. The method of claim 1 , further comprising

f. screening the recombinant antibodies of (e) and selecting those which reduce GDF-8 growth factor activity.

7. The method of claim 6 , wherein said enzymatic cleavage comprises sequential enzymatic cleavage with at least two enzymes.

Assignments (2)
SECURITY INTEREST Recorded Mar 3, 2026
From: SCHOLAR ROCK, INC.
To: LSI FINANCING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 075015/0854 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2015
From: SCHURPF, THOMAS; MAHANTHAPPA, NAGESH K.; STRAUB, MICHELLE MARIE
To: SCHOLAR ROCK, INC.
Reel/Frame 037202/0582 →
Continuity (5)
Continuation PCTUS2014036933 · May 6, 2014
Provisional Application 61819840 · May 6, 2013
Provisional Application 61823552 · May 15, 2013
Provisional Application 61900438 · Nov 6, 2013
Related Publication 20150337034A1 · Nov 26, 2015